Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRACE-LE: TNT with Envafolimab and Split-Course RT for Very Low Rectal Cancer
NCT05969847Phase 2Not yet recruiting
- Sponsor
- Chipan Biotech
- Start
- Aug 2023
- Primary completion
- Dec 2027
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of envafolimab in rectal cancer, sponsored by Chipan Biotech. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
envafolimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT05969847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05969847.